Amneal Pharmaceuticals (AMRX) Stock Forecast & Price Target

Amneal Pharmaceuticals is supported by a strong operating mix in which Affordable Medicines contributes the majority of revenue and is shifting toward more complex injectables, inhalables, and biosimilars that carry better durability and margins, while recent approvals and a 2025 launch cadence support continued growth. Its Specialty segment adds a second growth engine, with CREXONT showing rapid uptake, about 400 new prescribers monthly, and management targeting 30%-40% U.S. market share over time, while BREKIYA and UNITHROID further diversify earnings. AvKARE remains a cash-generative stabilizer, and with adjusted EBITDA beating expectations in 3Q and estimates rising to $3.24Bn sales in 2026 and $3.55Bn in 2027, the company appears positioned for sustained top-line growth and margin expansion.

Amneal Pharmaceuticals is viewed negatively because its growth thesis depends on several uncertain catalysts that have yet to prove durable, including a late 2027 XOLAIR biosimilar launch, CREXONT adoption, and a steady cadence of generic filings and launches. Reported biosimilar revenue declined about 20% in 2025, so the 2030 growth goal requires a sharp reversal rather than continuation of current trends, while lower operating cash flow from heavier inventory investment and collections shifting into 1Q'27 raises execution and cash-conversion risk. The company also faces looming competitive pressure, with RYTARY expected to lose its current protection in 2027, which could accelerate revenue and EBIT erosion if biosimilar pricing, volume gains, or specialty launches disappoint.